deltatrials

Non-small cell lung cancer Trials in Zunyi, China

Conditions / Non-small cell lung cancer / Zunyi, China

Non-small cell lung cancer has been the subject of sustained clinical investigation across multiple research sites.

13 total trials for this combination

Showing top 10 of 13 trials

Trials

NCT ID Title Status Phase
NCT06300177 D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure RECRUITING PHASE3
NCT05922345 Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. RECRUITING PHASE3
NCT06984588 A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING PHASE2/PHASE3
NCT03594747 A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer COMPLETED PHASE3
NCT03663205 A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer COMPLETED PHASE3
NCT03358875 Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) COMPLETED PHASE3
NCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT03447769 Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A TERMINATED PHASE3
NCT06496490 A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality RECRUITING PHASE2
NCT05042375 A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer UNKNOWN PHASE3

Related Pages